These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36368321)

  • 21. MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma.
    Pitolli C; Marini A; Guerra M; Pieraccioli M; Marabitti V; Palluzzi F; Giacò L; Tamburrini G; Cecconi F; Nazio F; Sette C; Pagliarini V
    J Exp Clin Cancer Res; 2023 Aug; 42(1):214. PubMed ID: 37599362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
    Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
    Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma.
    Maynard RE; Poore B; Hanaford AR; Pham K; James M; Alt J; Park Y; Slusher BS; Tamayo P; Mesirov J; Archer TC; Pomeroy SL; Eberhart CG; Raabe EH
    Cancer Lett; 2021 Apr; 504():137-145. PubMed ID: 33571541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma.
    Brun SN; Markant SL; Esparza LA; Garcia G; Terry D; Huang JM; Pavlyukov MS; Li XN; Grant GA; Crawford JR; Levy ML; Conway EM; Smith LH; Nakano I; Berezov A; Greene MI; Wang Q; Wechsler-Reya RJ
    Oncogene; 2015 Jul; 34(29):3770-9. PubMed ID: 25241898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells.
    Valinciute G; Ecker J; Selt F; Hielscher T; Sigaud R; Ridinger J; Thatikonda V; Gatzweiler C; Robinson S; Talbot J; Bernardi F; Picard D; Blattner-Johnson M; Schmid S; Jones DT; van Tilburg CM; Capper D; Kool M; Remke M; Oehme I; Pfister SM; Roussel MF; Ayrault O; Witt O; Milde T
    J Neurooncol; 2023 May; 163(1):143-158. PubMed ID: 37183219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
    Singh AR; Joshi S; Zulcic M; Alcaraz M; Garlich JR; Morales GA; Cho YJ; Bao L; Levy ML; Newbury R; Malicki D; Messer K; Crawford J; Durden DL
    PLoS One; 2016; 11(3):e0150836. PubMed ID: 26938241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells.
    von Bueren AO; Shalaby T; Rajtarova J; Stearns D; Eberhart CG; Helson L; Arcaro A; Grotzer MA
    BMC Cancer; 2007 Jan; 7():19. PubMed ID: 17254356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.
    Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP
    Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting B7‑H3 through EZH2 inhibition in MYC‑positive Group 3 medulloblastoma.
    Shishido K; Purvis IJ; Velpula KK; Venkataraman S; Vibhakar R; Asuthkar S
    Oncol Rep; 2023 Jun; 49(6):. PubMed ID: 37114557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RNA interference screening identifies a novel role for PCTK1/CDK16 in medulloblastoma with c-Myc amplification.
    Ćwiek P; Leni Z; Salm F; Dimitrova V; Styp-Rekowska B; Chiriano G; Carroll M; Höland K; Djonov V; Scapozza L; Guiry P; Arcaro A
    Oncotarget; 2015 Jan; 6(1):116-29. PubMed ID: 25402633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Proteogenomic Approach to Understanding MYC Function in Metastatic Medulloblastoma Tumors.
    Staal JA; Pei Y; Rood BR
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting protein folding in N-Myc-driven medulloblastoma.
    Valinciute G; Roussel MF
    Mol Oncol; 2023 Mar; 17(3):387-389. PubMed ID: 36786675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BMI1 is a therapeutic target in recurrent medulloblastoma.
    Bakhshinyan D; Venugopal C; Adile AA; Garg N; Manoranjan B; Hallett R; Wang X; Mahendram S; Vora P; Vijayakumar T; Subapanditha M; Singh M; Kameda-Smith MM; Qazi M; McFarlane N; Mann A; Ajani OA; Yarascavitch B; Ramaswamy V; Farooq H; Morrissy S; Cao L; Sydorenko N; Baiazitov R; Du W; Sheedy J; Weetall M; Moon YC; Lee CS; Kwiecien JM; Delaney KH; Doble B; Cho YJ; Mitra S; Kaplan D; Taylor MD; Davis TW; Singh SK
    Oncogene; 2019 Mar; 38(10):1702-1716. PubMed ID: 30348991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
    Song H; Bhakat R; Kling MJ; Coulter DW; Chaturvedi NK; Ray S; Joshi SS
    Biochem Biophys Res Commun; 2019 Dec; 520(2):250-256. PubMed ID: 31594641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma.
    Kameda-Smith MM; Zhu H; Luo EC; Suk Y; Xella A; Yee B; Chokshi C; Xing S; Tan F; Fox RG; Adile AA; Bakhshinyan D; Brown K; Gwynne WD; Subapanditha M; Miletic P; Picard D; Burns I; Moffat J; Paruch K; Fleming A; Hope K; Provias JP; Remke M; Lu Y; Reya T; Venugopal C; Reimand J; Wechsler-Reya RJ; Yeo GW; Singh SK
    Nat Commun; 2022 Dec; 13(1):7506. PubMed ID: 36473869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma.
    Bandopadhayay P; Piccioni F; O'Rourke R; Ho P; Gonzalez EM; Buchan G; Qian K; Gionet G; Girard E; Coxon M; Rees MG; Brenan L; Dubois F; Shapira O; Greenwald NF; Pages M; Balboni Iniguez A; Paolella BR; Meng A; Sinai C; Roti G; Dharia NV; Creech A; Tanenbaum B; Khadka P; Tracy A; Tiv HL; Hong AL; Coy S; Rashid R; Lin JR; Cowley GS; Lam FC; Goodale A; Lee Y; Schoolcraft K; Vazquez F; Hahn WC; Tsherniak A; Bradner JE; Yaffe MB; Milde T; Pfister SM; Qi J; Schenone M; Carr SA; Ligon KL; Kieran MW; Santagata S; Olson JM; Gokhale PC; Jaffe JD; Root DE; Stegmaier K; Johannessen CM; Beroukhim R
    Nat Commun; 2019 Jun; 10(1):2400. PubMed ID: 31160565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.
    Venkataraman S; Alimova I; Balakrishnan I; Harris P; Birks DK; Griesinger A; Amani V; Cristiano B; Remke M; Taylor MD; Handler M; Foreman NK; Vibhakar R
    Oncotarget; 2014 May; 5(9):2355-71. PubMed ID: 24796395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137.
    Wang J; Sui Y; Li Q; Zhao Y; Dong X; Yang J; Liang Z; Han Y; Tang Y; Ma J
    Cell Death Dis; 2020 Dec; 11(12):1029. PubMed ID: 33268769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The alkylphospholipid perifosine induces apoptosis and p21-mediated cell cycle arrest in medulloblastoma.
    Kumar A; Fillmore HL; Kadian R; Broaddus WC; Tye GW; Van Meter TE
    Mol Cancer Res; 2009 Nov; 7(11):1813-21. PubMed ID: 19887560
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Tao R; Murad N; Xu Z; Zhang P; Okonechnikov K; Kool M; Rivero-Hinojosa S; Lazarski C; Zheng P; Liu Y; Eberhart CG; Rood BR; Packer R; Pei Y
    Cancer Res; 2019 Apr; 79(8):1967-1980. PubMed ID: 30862721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.